Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Aberrant Proportion of Monocyte Subsets in Bone Marrow of High-Risk Myelodysplastic Syndrome Patients

Richa Rai, Camille Bigenwald, Jonathan Feld, Stella Melana, Erin P. Demakos, Amir Horowitz, Lewis R. Silverman

Blood (2022) 140 (Supplement 1): 11432–11433.

https://doi.org/10.1182/blood-2022-170922

Published: 2022

Journal Articles

Combination of Ras Modulator and Azacitidine Impacts Innate Immune Signaling Pathway in MDS-L Cell Line

Richa Rai, Foramben Patel, Jonathan Feld, Stella Melana, Shyamala C. Navada, Rosalie Odchimar-Reissig, Erin P. Demakos, E. Premkumar Reddy, Lewis R. Silverman

Blood (2021) 138 (Supplement 1): 4325.

https://doi.org/10.1182/blood-2021-152764

Published: 2021

Journal Articles

Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line

Richa Rai, PhD, Foramben Patel, MS, Stella Melana, PhD, Jonathan Feld, MD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, E. Premkumar Reddy, PhD, Lewis R. Silverman, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-142908

Published: 2020

Journal Articles

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic

Jonathan Feld, MD, Erin P. Demakos, RN, Rosalie Odchimar-Reissig, RN, Douglas Tremblay, MD, Saudia Alli, NP, Darshanie Sewah, RN, Shyamala C. Navada, MD, Lewis R. Silverman, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-138969

Published: 2020

Journal Articles

Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)

Camille Bigenwald, MD, Amir Horowitz, PhD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Richa Rai, PhD, Stella Melana, PhD, Erin P. Demakos, RN, Miriam Merad, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 2986.

https://doi.org/10.1182/blood-2019-124887

Published: 2019

Journal Articles

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

Jonathan Feld, MD, Francesca Schieppati, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, Shyamala C. Navada, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4260.

https://doi.org/10.1182/blood-2019-128656

Published: 2019

Journal Articles

The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome

Richa Rai, PhD, Stella Melana, PhD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, E. Premkumar Reddy, PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4231.

https://doi.org/10.1182/blood-2019-130747

Published: 2019

Journal Articles

Sequential Treatment with Rigosertib Followed By Azacitidine Maximizes the Effects on the Interferon Signaling Pathway in Hematopoietic Cells in Myelodysplastic Syndrome (MDS)

Richa Rai, PhD, Stella Melana, PhD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, E. Premkumar Reddy, PhD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 5500.

https://doi.org/10.1182/blood-2018-99-119266

Published: 2018

Journal Articles

Effects of Rigosertib (RIGO) Alone or in Combination with Azacitidine or Vorinostat on Epigenetic Reprogramming of CD34+ Cells in the Myelodysplastic Syndrome

Lewis R Silverman, MD, Pratima Chaurasia, PhD, Stella Melana, PhD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, BA, BSN, MSN, RN, Shyamala C. Navada, MD, E. Premkumar Reddy, PhD BSc, MSc

Blood (2017) 130 (Supplement 1): 4235.

https://doi.org/10.1182/blood.V130.Suppl_1.4235.4235

Published: 2017

Journal Articles

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Katherine P. Hearn, BSN, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney D DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Pierre Fenaux, MD PhD, Michael E. Petrone, MD MPH, Patrick Simon Zbyszewski, MBA, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2016) 128 (22): 3167.

https://doi.org/10.1182/blood.V128.22.3167.3167

Published: 2016

Journal Articles

A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)

Shyamala C. Navada, MD, Lewis R. Silverman, MD, Katherine P. Hearn, BSN, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Tapan Kadia, MD, Pierre Fenaux, MD PhD, Steve Fruchtman, MD, Nozar Azarnia, PhD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 910.

https://doi.org/10.1182/blood.V126.23.910.910

Published: 2015

Journal Articles

Intravenous Immunoglobulin Is an Effective Treatment for LGL-Mediated Immune Cytopenias in Myelodysplastic Syndromes and Other Bone Marrow Failure Syndromes

Francesca Schieppati, Erin P. Demakos, RN, CCRN, Odchimar Rosalie-Reissig, RN, Shyamala C. Navada, MD, Lewis R. Silverman, MD

Blood (2015) 126 (23): 1704.

https://doi.org/10.1182/blood.V126.23.1704.1704

Published: 2015

Journal Articles

A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Francois Wilhelm, MD PhD, Katherine Hearn, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney D. DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Nozar Azarnia, PhD, Lewis R. Silverman, MD

Blood (2014) 124 (21): 3252.

https://doi.org/10.1182/blood.V124.21.3252.3252

Published: 2014

Journal Articles

Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents

Erin P. Demakos, RN, CCRN, Lewis R. Silverman, MD, Moira E. Lawrence, PhD, Thomas J. McKearn, MD PhD, Scott Megaffin, Rita Percy, Michael E. Petrone, MD MPH

Blood (2014) 124 (21): 1287.

https://doi.org/10.1182/blood.V124.21.1287.1287

Published: 2014

Journal Articles

Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents

Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, E. Premkumar Reddy, PhD, Erin P Demakos, RN, CCRN, James F Holland, MD, Francois Wilhelm, MD, PhD., Lewis R. Silverman, MD

Blood (2013) 122 (21): 1527.

https://doi.org/10.1182/blood.V122.21.1527.1527

Published: 2013

Journal Articles

A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium

Lewis R. Silverman, MD, Amit Verma, MD, Rosalie Odchimar-Reissig, RN, Eric J. Feldman, MD, Shyamala C. Navada, MD, Erin P Demakos, RN, Maria R. Baer, MD, Vesna Najfeld, PhD, Joseph A Sparano, MD, Richard Piekarz, MD, PhD

Blood (2013) 122 (21): 386.

https://doi.org/10.1182/blood.V122.21.386.386

Published: 2013

Journal Articles

Dose Escalation of Azacitidine in Patients Failing Standard or Investigational Combinations of the Agent in the Myelodysplastiic Syndrome or Evolved AML

Lewis R. Silverman, MD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Maria Michalak, PA-C, Erin P Demakos, RN, CCRN, James F Holland, MD

Blood (2012) 120 (21): 4932.

https://doi.org/10.1182/blood.V120.21.4932.4932

Published: 2012

Journal Articles

Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis

Blood (2011) 118 (21): 1750.

https://doi.org/10.1182/blood.V118.21.1750.1750

Published: 2011

Journal Articles

A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC).

Elizabeth Hexner, MD, Judith D. Goldberg, Sc.D., Josef T. Prchal, MD, Erin P Demakos, RN, Sabina Swierczek, Ph.D., Rona Singer Weinberg, PhD, Joseph Tripodi, M.S., Vesna Najfeld, Ph.D., Martin Carroll, MD, Roberto Marchioli, MD, Lewis R. Silverman, MD, Ronald Hoffman, MD

Blood (2009) 114 (22): 754.

https://doi.org/10.1182/blood.V114.22.754.754

Published: 2009

Journal Articles

Analysis of Survival, AML Transformation, and Transfusion Independence in Patients with High-Risk Myelodysplastic Syndromes (MDS) Receiving Azacitidine Determined Using a Prognostic Model.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Erin P. Demakos, RN, CCRC, James F. Holland, MD, Richard R. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2523.

https://doi.org/10.1182/blood.V106.11.2523.2523

Published: 2005

NARROW

Aberrant Proportion of Monocyte Subsets in Bone Marrow of High-Risk Myelodysplastic Syndrome Patients

Combination of Ras Modulator and Azacitidine Impacts Innate Immune Signaling Pathway in MDS-L Cell Line

Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic

Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome

Sequential Treatment with Rigosertib Followed By Azacitidine Maximizes the Effects on the Interferon Signaling Pathway in Hematopoietic Cells in Myelodysplastic Syndrome (MDS)

Effects of Rigosertib (RIGO) Alone or in Combination with Azacitidine or Vorinostat on Epigenetic Reprogramming of CD34+ Cells in the Myelodysplastic Syndrome

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)

Intravenous Immunoglobulin Is an Effective Treatment for LGL-Mediated Immune Cytopenias in Myelodysplastic Syndromes and Other Bone Marrow Failure Syndromes

A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents

Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents

A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium

Dose Escalation of Azacitidine in Patients Failing Standard or Investigational Combinations of the Agent in the Myelodysplastiic Syndrome or Evolved AML

Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis

A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC).

Analysis of Survival, AML Transformation, and Transfusion Independence in Patients with High-Risk Myelodysplastic Syndromes (MDS) Receiving Azacitidine Determined Using a Prognostic Model.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only